Ovid Therapeutics and University of Connecticut Collaborate to Accelerate the Development of OV101 (gaboxadol) for Angelman Syndrome
Shots:
- Ovid will collaborate with UConn’s Stormy J. Chamberlain and secures exclusive access to identified genetic sequences for shRNA-based therapy. Ovid plans to leverage its translational medicine capabilities and drug development expertise in Angelman syndrome to advance OV101 into clinical
- Ovid is developing OV101 for Angelman syndrome to restore tonic inhibition addressing several core symptoms of the disease. OV101 is currently being evaluated in P-III NEPTUNE study with expected results in Q4’20
- Additionally- Ovid is exploring OV881- a microRNA approach that may reduce the expression of UBE3A-antisense and restores UBE3A expression while the company is developing OV935 (soticlestat) in collaboration with Takeda for rare developmental and epileptic encephalopathies (DEE)
Ref: Ovid Therapeutics | Image: Ovid Therapeutics
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
